首页> 外文期刊>Nature reviews. Urology >Systemic treatments for high-risk localized prostate cancer
【24h】

Systemic treatments for high-risk localized prostate cancer

机译:高危局部前列腺癌的全身治疗

获取原文
获取原文并翻译 | 示例
           

摘要

The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes. However, although the combination of androgen deprivation therapy and radiotherapy is a standard of care in high-risk localized or locally advanced prostate cancer, the benefit of chemotherapy or chemohormonal therapy has yet to be demonstrated outside of the metastatic setting. Moreover, the benefit of neoadjuvant and/or adjuvant systemic therapies in combination with radical prostatectomy has not been proved. The development of next-generation hormonal agents, which have been approved for the treatment of castration-resistant prostate cancer, offers further therapeutic possibilities that are being assessed in early-phase clinical trials.
机译:随后发展致命转移性疾病的前列腺癌的大多数患者在介绍时具有高危局部疾病,强调了在本阶段的有效治疗策略的重要性。组合系统性和局部疗法的多模式处理方法提供了改善高风险局部前列腺癌患者的临床结果的有希望的策略。 Neoadjuvant和佐剂化疗的组合,荷尔蒙治疗或化学侵犯疗法被认为是大多数实体瘤中的护理标准,并且应该在将来调查,以治疗前列腺癌以改善患者结果。然而,尽管雄激素剥夺治疗和放射治疗的组合是高危局部或局部晚期前列腺癌的护理标准,但化疗或化学侵犯疗法的益处尚未在转移环境之外展示。此外,尚未证明Neoadjuvant和/或佐剂系统疗法与自由基前列腺切除术的益处。已经批准用于治疗阉割前列腺癌的下一代激素剂的发展提供了在早期临床试验中评估的进一步治疗可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号